<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131467</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE-PER-CD</org_study_id>
    <nct_id>NCT02131467</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Perampanel in Cervical Dystonia</brief_title>
  <official_title>An Open-label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel (E2007) in Subjects With Cervical Dystonia (SAFE-Per CD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dystonia Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical dystonia (CD) is the most common focal dystonia. Currently there are no effective
      oral medications for the treatment of CD. While botulinum toxin injections improve symptoms,
      they require repeated injections by a trained physician and some patients stop responding to
      injections or never respond at all. Therefore, alternative treatment options for CD are
      needed. One new agent is a drug that targets glutamate receptors that are thought to be
      involved dystonia. This drug, perampanel, was originally developed for epilepsy and is
      licensed for use in the USA and Canada for treating epilepsy. The purpose of this study is to
      test the effectiveness of perampanel in treating the symptoms of CD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic cervical dystonia (CD) is the most common form of focal dystonia with a prevalence
      of approximately 60 cases per million population.(Nutt et al.,1988). Current oral medical
      treatments for CD have variable efficacy and often with marked side effects. Botulinum toxin
      injections may be more effective than pharmacological therapies, and are currently the best
      available therapeutic option. However, repeat injections, administered by a physician trained
      in this area are required every 3-4 months.(Brans et al.,1996) This can often be difficult
      and costly for patients. Furthermore, there are subgroups of patients who simply do not
      respond to this treatment and between 5-20% of patients may become secondary non responders
      due to the development of blocking antibodies to the botulinum toxin.(Mejia et al., 2005)
      Thus, new therapeutic options are required.

      The neural mechanisms underlying idiopathic dystonia are not well known. Classical basal
      ganglia circuitry models predict underactivity of the output regions of the basal ganglia,
      the medial globus pallidus and substantia nigra pars reticulata (;Mitchell et al 1990). In
      subjects with dystonia undergoing DBS, intraoperative recordings have demonstrated
      underactivity of the medial globus pallidus (Vitek et al, 1999, Lozano et al 1997). One
      mechanism responsible for these basal ganglia output changes may be overactivity of
      corticostriatal glutamatergic pathways, as similar neural mechanism are thought to underlie
      other hyperkinetic movements (Brotchie 2005). The best studied hyperkinetic movement disorder
      is levodopa-induced dyskinesia in Parkinson's disease in which dystonia, often of the head
      and neck, may occur. In animal models of levodopa-induced dyskinesia, increased striatal
      glutamatergic signaling via alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid
      (AMPA) receptors has been demonstrated (Perier et al 2002, Silverdale et al 2010). To date
      there are few validated animal models of idiopathic dystonia. However, one model that has
      been use for pharmacological studies, and the results extrapolated to idiopathic dystonia, is
      the paroxysmal dt(sz) dystonic hamster (Loscher and Richter 1998). In this model,
      intrastriatal and systemic injection of NBQX a selective AMPA receptor antagonist reduced
      dystonic severity (Richter et al 1993, Sander and Richter 2002, Kohling et al 2004). Other
      studies have suggested that cerebellar outflow pathways, using AMPA receptors may also
      mediate dystonic symptoms. Thus the excitatory amino-acid kainite injected into rodent
      cerebellar vermis resulted in dystonic symptoms, an effect revered by NBQX, suggesting an
      action on AMPA receptors (Pizoli et al 2002). Thus AMPA receptor antagonists may alleviate
      dystonia.

      To date, clinical studies using glutamate antagonists in CD have been limited due to lack of
      available drugs. A single 6-week open-label pilot study of the non-selective glutamate
      antagonist riluzole (50 mg twice a day) in six patients with cervical dystonia (CD) reported
      a 26% improvement in CD with no side-effects (Muller et al 2002).

      The aim of this study is to conduct a multicentre phase I/IIa open label study to determine
      the safety and tolerability of the AMPA antagonist, perampanel in subjects with primary
      cervical dystonia. Exploratory analysis will determine effects on dystonia disability and
      subjective measures including quality of life and global impression of change. The importance
      of such an initial safety study is due to the lack of knowledge related to the use of this
      class of drug (AMPA antagonist) in this population of patients. The longer term aim is thus
      to generate preliminary data for further randomised controlled efficacy studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects able to remain on study drug for minimum of 4 weeks.</measure>
    <time_frame>Measured at week 12.</time_frame>
    <description>Tolerability will be assessed by counting number of subjects able to remain on drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated as the cumulative number of new adverse events collected at each visit from Baseline to visit 4</measure>
    <time_frame>Adverse events at study visits weeks 0, 2, 6, 8, 9, 10 and 12</time_frame>
    <description>Adverse events will be assessed at each visit by direct questioning patients, measuring weight, vital signs, Hamilton depression scale and laboratory tests and ECG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline to end of maintenance in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)</measure>
    <time_frame>week 12</time_frame>
    <description>The TWSTRS is a validated rating scale that measures disability due to cervical dystonia.</description>
  </other_outcome>
  <other_outcome>
    <measure>CDIP58</measure>
    <time_frame>week 12</time_frame>
    <description>Change in impact of Cervical Dystonia on quality of life using the CDIP 58 from baseline to end of maintenance</description>
  </other_outcome>
  <other_outcome>
    <measure>CGI</measure>
    <time_frame>week 12</time_frame>
    <description>Change in Clinical global Impression (CGI) of Cervical Dystonia severity (patient and investigator) from baseline to end of maintenance</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Perampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>oral drug</description>
    <arm_group_label>Perampanel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 year old male and female patients with primary cervical dystonia.

          -  Can treated with botulinum toxin but at least 8 weeks (+ 1 week) from a previous
             injection.

          -  Subjects may be on stable anti-dystonia treatment (for at least one month) including
             anticholinergics, baclofen, anxiolytics including benzodiazepines.

        Exclusion Criteria:

          -  Secondary cervical dystonia,

          -  Cognitive impairment (Montreal Cognitive assessment MOCA) &lt; 26;

          -  Active psychosis;

          -  History of aggression;

          -  Active depression (Hamilton Depression Rating Scale (HDRS) score â‰¥ 12).

          -  Current use of alcohol,

          -  Substance abuse (current or prior);

          -  Inability to stop driving for duration of study;

          -  Active infection,

          -  Hypersensitivity to perampanel,

          -  Significant renal dysfunction (Creatinine clearance &lt; 50ml/min),

          -  Significant laboratory abnormalities (ALT or AST greater than twice normal value;
             elevated bilirubin, active liver disease: hepatitis, cholestasis, cirrhosis, etc),

          -  Significant medical illness,

          -  Women who are pregnant or plan to become pregnant, women who are breastfeeding,

          -  Subjects who do not agree to avoid consumption of grapefruit or grapefruit-containing
             products throughout the study,

          -  Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption

          -  Use of prohibited medications known to be inducers of CYP3A including, but not limited
             to: rifampicin, troglitazone, St John's Wort, efavirenz, nevirapine, barbiturates,
             glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin;
             and any other interactions as per Product Monograph
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan H Fox, MRCP(UK), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan H Fox, MRCP(UK), PhD</last_name>
    <phone>416 603 6422</phone>
    <email>sfox@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandon Rothberg</last_name>
    <phone>416 603 5800</phone>
    <phone_ext>3120</phone_ext>
    <email>brothber@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Buz Jinnah, MD PhD</last_name>
      <email>hjinnah@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Buz Jinnah, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Comella, MD</last_name>
      <email>Cynthia_Comella@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Chmura</last_name>
      <email>Teresa_Chmura@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy Comella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Swan, MD</last_name>
      <email>Matthew.Swan@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Ramirez</last_name>
      <email>laura.ramirez@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Swan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert Fernandez, MD</last_name>
      <email>FERNANH@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Hubert Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Fox</last_name>
      <email>sfox@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Brandon Rothberg</last_name>
      <email>brothber@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

